logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
S

Sylvie Chabaud

centre leon berard

46H-index
366Paper Count
1.0WCitation Count
Published Papers 123
Publication Date
logo
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis
errEuropean Urology
IF25.2
err2026-07-28
err0
PREAI
errAmar U. Kishan; Yilun Sun; Christopher C. Parker; Paul Sargos; Matthew Sydes; Sylvie Chabaud; Meryem Brihoum; Stephane Supiot; Igor Latorzeff; Stephane Guerif; Tahmineh Romero Kalbasi; Michael L. Steinberg; Luca F. Valle; Kekoa Taparra; Matthew J. Farrell; Jonathan E. Shoag; Jorge A. Garcia; Jason R. Brown; Matthew B. Rettig; Adam E. Singer
errShare
errSave
COVID-19 Vaccination Before Immune Checkpoint Inhibitor Initiation and the Overall Survival of Patients with Advanced Cancer: a cohort study
errEuropean Journal of Cancer
IF7.1
err2026-05-06
err0
PREAI
errPierre-Etienne Heudel; Virginie Avrillon; Benedicte Mastroianni; Helen Boyle; Souad Assaad; Isabelle Ray-Coquard; Jean-Philippe Spano; Sylvie Chabaud; Claire Cropet; Maurice Perol; Jean-Yves Blay
errShare
errSave
Cabozantinib in Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma: Results of the Multicenter Phase II Trial CABRAMET
errEuropean Journal of Cancer
IF7.1
err2026-04-01
err0
PREAI
errSylvie Negrier; Loïc Mourey; Cécile Dalban; Marine Gross-Goupil; Aude Fléchon; Bernard Escudier; Philippe Barthélémy; Stéphane Oudard; Emeline Colomba; Constance Thibault; Alain Ravaud; Christine Chevreau; Helen Jane Boyle; Ellen Blanc; Sylvie Chabaud; David Pérol; Laurence Albiges; Ronan Flippot
errShare
errSave
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03
errThe Breast
IF0
err2025-11-21
err0
errOAAI
errOlivier Trédan; Delphine Loirat; Sylvie Chabaud; Philippe Toussaint; Thierry Petit; Frédéric Viret; Christelle Levy; Aurélien Robert; Julien Grenier; Laura Mansi; Jean-Philippe Spano; Anne Patsouris; Olfa Derbel; Christelle Jouannaud; Jean Marc Ferrero; Jean Sébastien Frenel; Yann Molin; Louis Doublet; Pierre-Etienne Heudel; Jean-Yves Pierga
errShare
errSave
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
errEuropean Urology
IF25.2
err2025-11-11
err0
PREAI
errRonan Flippot; Yann-Alexandre Vano; Cécile Dalban; Benoit Beuselinck; Aude Fléchon; Maxime Meylan; Damien Pouessel; Antoine Bougoüin; Catherine Sautes-Fridman; Gwenaelle Gravis; Nathalie Chaput; Stéphane Oudard; Aude Desnoyer; Brigitte Laguerre; Salem Chouaib; Philippe Barthelemy; Delphine Borchiellini; Lucia Carril-Ajuria; Marine Gross-Goupil; Wolf-Herman Fridman; Lionnel Geoffrois; Frederic Rolland; Antoine Thiery-Vuillemin; Florence Joly; Sylvain Ladoire; Florence Tantot; Sylvie Chabaud; Bernard Escudier; Nathalie Rioux-Leclercq; Laurence Albiges
errShare
errSave
Estimating overall survival by combining administrative and hospital death data: a methodological challenge
errEuropean Journal of Epidemiology
IF5.9
err2025-10-21
err0
PREAI
errPierre-Yves Cren; Clémence Leguillette; Franck Craynest; Ali Hammoudi; Maël Barthoulot; Matthieu Carton; Thomas Filleron; Sylvie Chabaud; Youenn Drouet; Marie-Cécile Le Deley
errShare
errSave
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial
errEuropean Urology
IF25.2
err2025-09-30
err0
PREAI
errAmar U. Kishan; Jesus E. Juarez Casillas; Paul Sargos; Tahmineh Romero Kalbasi; Sylvie Chabaud; Meryem Brihoum; Ankush Sachdeva; John N. Nikitas; T.Martin Ma; Danielle Karasik; Leslie K. Ballas; Derrick Lock; Luca Valle; Kekoa Taparra; Robert E. Reiter; Christopher Saigal; Karim Chamie; Nicholas Donin; Arnold I. Chin; Matthew Rettig; Nicholas G. Nickols; Yilun Sun; Daniel Spratt; James M. Lamb; Minsong Cao; Pascal Pommier; Michael L. Steinberg
errShare
errSave
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2− Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial
errClinical Pharmacology & Therapeutics
IF5.5
err2025-08-24
err0
PREAI
errEnora Laas; Anne-Sophie Hamy; Thomas Bachelot; Paul Gougis; Jérôme Lemonnier; Fabrice André; David Cameron; Judith Bliss; Sylvie Chabaud; Anne-Claire Hardy-Bessard; Magali Lacroix-Triki; Djelila Allouache; Marc Debled; Mario Campone; Laurence Venat-Bouvet; Paul Cottu; Mathilde Martinez; Julien Grenier; Florence Dalenc; Elise Dumas; Fabien Reyal; Bernard Asselain; Frédérique Penault-Llorca; Francis Lévi; Sylvie Giacchetti
errShare
errSave
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
errEuropean Urology
IF25.2
err2025-06-26
err0
errOAAI
errSarah Burdett; David J. Fisher; Jayne F. Tierney; Adrian D. Cook; Daniel E. Spratt; James J. Dignam; Wendy F. Seiferheld; Amar U. Kishan; Yilun Sun; Sylvie Chabaud; Jason A. Efstathiou; Christopher C. Parker; Alan Pollack; Paul Sargos; Igor Latorzeff; Meryem Brihoum; Charles N. Catton; Noel W. Clarke; Felix Y. Feng; Theodore G. Karrison; Pascal Pommier; Howard M. Sandler; Matthew R. Sydes; Claire L. Vale
errShare
errSave
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2025-06-01
err0
errOAAI
errBelkaid, Samy; Ribereau-Gayon, Emmanuel; Chabaud, Sylvie; Anriot, Julien; Chalas, Thibald; Flechon, Aude; Boyle, Helen; Vinceneux, Armelle; Berard, Frederic; You, Benoit; Freyer, Gilles; Darnis, Sophie; Tartas, Sophie; Amini-Adle, Mona
errShare
errSave
COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials
errESMO Open
IF8.3
err2025-06-01
err0
PREAI
errF. Rethouze; S. Risbourg; C. Schiffler; S. Chabaud; A. de Courrèges; M.-C. Le Deley; J.Y. Blay; F. Feutry; M. Jimenez; M. Vanseymortier; N. Penel; F. Duffaud; L. Lebellec
errShare
errSave
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
errAnnals of Oncology
IF65.4
err2025-05-28
err0
errOAAI
errJ.-Y. Blay; Q. Devin; M. Toulmonde; A. Dufresne; N. Penel; A. Adenis; M. Rios; F. Bertucci; F. Duffaud; N. Firmin; T. Valentin; E. Bompas; O. Collard; M. Pracht; A. Hervieu; B. Verret; I. Ray-Coquard; P. Cassier; C. Henon; D. Perol; A. Italiano; S. Chabaud; A. Le Cesne
errShare
errSave
Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse
errANNALS OF ONCOLOGY
IF65.4
err2025-01-01
err0
PREAI
errBlay, J. -y.; Penel, N.; Schif, C.; Chabaud, S.; Perol, D.; Le Cesne, A.
errShare
errSave
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
errANNALS OF ONCOLOGY
IF65.4
err2024-12-01
err6
errOAAI
errBlay, J. -y.; Schiffler, C.; Bouche, O.; Brahmi, M.; Duffaud, F.; Toulmonde, M.; Landi, B.; Lahlou, W.; Pannier, D.; Bompas, E.; Bertucci, F.; Chaigneau, L.; Collard, O.; Pracht, M.; Henon, C.; Ray-Coquard, I.; Armoun, K.; Salas, S.; Spalato-Ceruso, M.; Adenis, A.; Verret, B.; Penel, N.; Moreau-Bachelard, C.; Italiano, A.; Dufresne, A.; Metzger, S.; Chabaud, S.; Perol, D.; Le Cesne, A.
errShare
errSave
Author's reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
errANNALS OF ONCOLOGY
IF65.4
err2024-12-01
err0
PREAI
errBlay, J. -y.; Schif, C.; Chabaud, S.; Perolc, D.; Le Cesne, A.
errShare
errSave
Role of the primary care physician in skin cancer screening: Perspectives of skin cancer patients
errANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
IF2.8
err2024-09-01
err0
errOAAI
errBelkaid, S.; Schenck, M.; Marcoux, M.; Chabaud, S.; Darnis, S.; Amini-Adle, M.
errShare
errSave
Trifluridine/tipiracil plus oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
errDIGESTIVE AND LIVER DISEASE
IF3.8
err2024-08-01
err0
errOAAI
errBotsen, Damien; Chabaud, Sylvie; Perrier, Herve; Ammarguellat, Hanifa; Jestin-Le-Tallec, Veronique; Olesinski, Jonathan; Toullec, Clemence; Aparicio, Thomas; Ben Abdelghani, Meher; Borg, Christophe; Bouche, Olivier; Coutzac, Clelia; Devaud, Herve; Di Fiore, Frederic; Dubreuil, Olivier; Evesque, Ludovic; Huguenin, Bruno; Muller, Marie; Poureau, Pierre-Guillaume; Oularue, Emilie; Tougeron, David; Zaanan, Aziz; Ammari, Samy; Carvalho, Nicolas De Sousa; Decazes, Pierre; De La Fouchardiere, Christelle
errShare
errSave
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
errEUROPEAN UROLOGY ONCOLOGY
IF9.3
err2024-08-01
err0
PREAI
errBillon, Emilien; Dalban, Cecile; Oudard, Stephane; Chevreau, Christine; Laguerre, Brigitte; Barthelemy, Philippe; Borchiellini, Delphine; Geoffrois, Lionnel; Negrier, Sylvie; Joly, Florence; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Rolland, Frederic; Priou, Frank; Mahammedi, Hakim; Tantot, Florence; Escudier, Bernard; Chabaud, Sylvie; Albiges, Laurence; Gravis, Gwenaelle
errShare
errSave
Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma
errESMO OPEN
IF8.3
err2024-08-01
err0
errOAAI
errDufresne, A.; Pokras, S.; Meurgey, A.; Chabaud, S.; Toulmonde, M.; Bompas, E.; Le Cesne, A.; Robin, Y. -M; Duffaud, F.; Valentin, T.; El Zein, S.; Leroux, A.; Dubray-Longeras, P.; Firmin, N.; de Pinieux, G.; Noal, S.; Delfour, C.; Bollard, J.; Tonon, L.; Biette, A.; Gadot, N.; Attignon, V.; Jean-Denis, M.; Woessner, M.; Klohe, E.; Thayaparan, T.; Eleftheriadou, I.; Blouch, K.; Nathenson, M. J.; Blay, J. -y.
errShare
errSave
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
errEBIOMEDICINE
IF10.8
err2024-06-01
err0
errOAAI
errGiacchetti, Sylvie; Laas, Enora; Bachelot, Thomas; Lemonnier, Jerome; Andre, Fabrice; Cameron, David; Bliss, Judith; Chabaud, Sylvie; Hardy-Bessard, Anne -Claire; Lacroix-Triki, Magali; Canon, Jean -Luc; Debled, Marc; Campone, Mario; Cottu, Paul; Dalenc, Florence; Ballesta, Annabelle; Penault-Llorca, Frederique; Asselain, Bernard; Dumas, Elise; Reyal, Fabien; Gougis, Paul; Levi, Francis; Hamy, Anne-Sophie
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
J
Jean‐Yves Blay
H-index: 158 · Papers: 2.4K
F
Fabrice André
H-index: 148 · Papers: 1.8K
D
Diether Lambrechts
H-index: 122 · Papers: 1.3K
R
Renzo Guerrini
H-index: 116 · Papers: 2.1K
J
Jaap Verweij
H-index: 115 · Papers: 1.1K
View more